News Overview

Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

USFDA's final approval is available for Zydus Lifesciences and group companies, and this will allow the group to sell the product in the highly regulated US market.

Tejas Networks stock has witnessed a total of 38% dip in the last one year, and 11% dip in the last one month.

Out of the total April 2025 sales, 24,833 units were sold locally and 2,491 units exported, a balanced input from the domestic and overseas market.

Net profit increased 34% YoY to ₹726.2 crore, bolstered by robust volume expansion and operating efficiency.

The solar projects are located across several states in India, enhancing Inox Green's pan-India renewable energy footprint.

As part of this offer, there is an offer for sale of up to 11.05 million Equity Shares.

On a quarter-on-quarter basis, the company’s net profit slipped 30.90% against ₹4,649 Crore in the previous quarter.

Praj informed the bourses that it has also established a Centre of Excellence (CoE) and Innovation for Biopolymers in collaboration with ICT Mumbai.